6 recruiting, 3 active not recruiting, 2 terminated, 1 not yet recruiting. 12 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Recruiting 6, Active not recruiting 3, Terminated 2, Not yet recruiting 1 |
| Phase 2 | 5 | Recruiting 3, Active not recruiting 1, Terminated 1 |
Follow Chest X-ray: new trials by email Literature Review of Chest X-ray trials Research Report on Chest X-ray
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 16 | 2027-04-17 | 2026-08-11 |
| FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 TCR/CD8ab-expressing T-cells, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 9 | 2026-12-01 | 2026-10-29 |
| Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma Bendamustine, Pralatrexate, Bone Marrow Aspiration - Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 50 | 2026-04-27 | 2026-05-11 |
| Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Autologous Anti-CD83 CAR T-cells, Biospecimen Collection, Chest Radiography - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Recruiting | Roswell Park Cancer Institute | 26 | 2026-02-02 | 2026-10-27 |
| Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Undifferentiated Leukemia | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 36 | 2025-09-23 | 2026-05-15 |
| Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas Anti-GARP Chimeric Antigen Receptor-T Cells, Biospecimen Collection, Chest Radiography - Recurrent Malignant Glioma, Recurrent WHO Grade 3 Glioma | Phase 1 | Recruiting | Ohio State University Comprehensive Cancer Center | 30 | 2025-05-21 | 2026-05-08 |
| Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan - Recurrent Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 37 | 2025-03-18 | 2026-06-25 |
| MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Multiple Myeloma | Phase 1 | Active not recruiting | Mayo Clinic | 16 | 2024-04-11 | 2026-08-17 |
| Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis Pre-operative abemaciclib, Device for Cerebral Fluid Dialysate Collection, Ashion Analytics GEM ExTra - Glioma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2023-04-07 | 2026-10-06 |
| T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR - Kita-kyushu Lung Cancer Antigen 1, Human | Phase 1 | Terminated | National Cancer Institute (NCI) | 36 | 2022-03-08 | 2025-12-02 |
| Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients Cyclophosphamide, Fludarabine, Aldesleukin - Gastrointestinal Cancer, Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 5 | 2019-05-16 | 2026-05-19 |
| MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 34 | 2014-04-25 | 2026-08-24 |
Leukemia, Myeloid, Acute (3) · Glioma (2) · Multiple Myeloma (2) · Brain Neoplasms (1) · Brenner Tumor (1) · Burkitt Lymphoma (1) · Carcinoma (1) · Colonic Neoplasms (1) · Fallopian Tube Neoplasms (1) · Gastrointestinal Neoplasms (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Lymphoma, T-Cell (1) · Myelodysplastic Syndromes (1) · Neoplasm Metastasis (1)
Fred Hutchinson Cancer Center (3) · Mayo Clinic (3) · National Cancer Institute (NCI) (3) · City of Hope Medical Center (1) · Ohio State University Comprehensive Cancer Center (1) · Roswell Park Cancer Institute (1)
United States (12)
Chelsea Peterson, DO (1) · Evanthia Galanis, MD (1) · Francesco Mazziotta, MD, PhD (1) · Ibrahim Aldoss (1) · James B Elder, MD (1) · James C Yang, M.D. (1) · Lorenzo Iovino, MD, PhD (1) · Moritz Binder, MD, MPH (1) · Naveed Ali, MD (1) · Sadhana Jackson, M.D. (1) · Scott M Norberg, D.O. (1) · Shaji K. Kumar, MD (1)
P01CA018029 (1), P30CA033572 (1), P50CA136393 (1), R01CA136547 (1), R01CA200507 (1)